Arnfin Bergmann, CEO at NeuroTransData GmbH, on the topic of 'DESTINY – An Innovative Platform for Personalized Medicine from Doctors for Doctors & Patients' at IFAH held at Le Meridien, Dubai on 16th - 18th December, 2019.
1. The document discusses using real-world big data (RWBD) from sources like insurance claims, EMRs, registries, and devices to analyze real-world treatment pathways and generate real-world evidence (RWE).
2. A case study analyzes longitudinal treatment pathways of patients with non-malignant multiple myeloma using Hadoop and MapReduce to query and merge data from large tables.
3. Visualizations of individual patient timelines and aggregate pathways show variability in treatments and outcomes that could help identify opportunities to improve care management and adherence to guidelines.
Big Data Analytics for Treatment Pathways John CaiJohn Cai
This document discusses using real-world big data analytics to understand treatment pathways. It begins by explaining the need for real-world evidence from real-world data to assess effectiveness and outcomes beyond randomized clinical trials. It then describes the volume, variety, and velocity characteristics of real-world big data from sources like claims, EMRs, surveys, and devices. Technical challenges of reconstructing complex patient journeys are discussed. Hadoop and MapReduce are presented as a potential solution by breaking the work into mappers that extract patient data and reducers that organize it into timelines. Examples are given of how this could enable cost, pathway, and outcomes analyses to better inform decision making.
The document is a presentation from Quest Diagnostics given at the UBS 2007 Global Life Sciences Conference. It summarizes that Quest Diagnostics is a leader in diagnostic testing and information technology solutions, touching over 150 million patient lives in 2006. It provides an overview of the company's network, services, growth opportunities around cancer diagnostics, personalized medicine, and near-patient testing, and approach to driving profitable growth.
Quest Diagnostics is the leader in diagnostic testing and information services in the United States. It touches over 150 million patient lives each year through comprehensive diagnostic testing services that help diagnose, monitor, predict, prevent, and treat diseases. Quest aims to be the undisputed world leader in diagnostic testing, information, and services through strategies focused on delivering superior patient experiences, leading medical innovation, leveraging its assets and capabilities, expanding diagnostic scope, and expanding its geographic reach.
Promoting Malaysia As A Trial Hub CRC As One Stop Centerleehanwei
The document summarizes Malaysia's efforts to promote clinical trials and establish itself as a regional clinical research hub. It outlines the Clinical Research Centre (CRC) as a one-stop center that can facilitate all aspects of conducting clinical trials in Malaysia, including providing investigator networks, regulatory and ethics submissions, data management, and other support services. CRC aims to make the clinical trials process efficient and help sponsors conduct trials in Malaysia. The document also highlights Malaysia's competitive advantages for clinical research such as its supportive government policies, qualified researchers, diverse patient populations, and lower costs.
When digital medicine becomes the medicine (2/2)Yoon Sup Choi
The study assessed the quality and accuracy of care provided by 8 major commercial telemedicine companies for common acute illnesses. Standardized patients presented 6 conditions and completed 599 virtual visits total. The completeness of histories and physical exams ranged from 51.7-82.4% across companies. Correct diagnoses were provided in 65.4-93.8% of visits. Adherence to clinical guidelines for management decisions was 54.3% overall but varied significantly between conditions and companies, from 34.4-66.1% across companies. Greater variation was seen for viral infections than musculoskeletal conditions. This suggests the quality of telemedicine can differ substantially between providers.
1. The document discusses using real-world big data (RWBD) from sources like insurance claims, EMRs, registries, and devices to analyze real-world treatment pathways and generate real-world evidence (RWE).
2. A case study analyzes longitudinal treatment pathways of patients with non-malignant multiple myeloma using Hadoop and MapReduce to query and merge data from large tables.
3. Visualizations of individual patient timelines and aggregate pathways show variability in treatments and outcomes that could help identify opportunities to improve care management and adherence to guidelines.
Big Data Analytics for Treatment Pathways John CaiJohn Cai
This document discusses using real-world big data analytics to understand treatment pathways. It begins by explaining the need for real-world evidence from real-world data to assess effectiveness and outcomes beyond randomized clinical trials. It then describes the volume, variety, and velocity characteristics of real-world big data from sources like claims, EMRs, surveys, and devices. Technical challenges of reconstructing complex patient journeys are discussed. Hadoop and MapReduce are presented as a potential solution by breaking the work into mappers that extract patient data and reducers that organize it into timelines. Examples are given of how this could enable cost, pathway, and outcomes analyses to better inform decision making.
The document is a presentation from Quest Diagnostics given at the UBS 2007 Global Life Sciences Conference. It summarizes that Quest Diagnostics is a leader in diagnostic testing and information technology solutions, touching over 150 million patient lives in 2006. It provides an overview of the company's network, services, growth opportunities around cancer diagnostics, personalized medicine, and near-patient testing, and approach to driving profitable growth.
Quest Diagnostics is the leader in diagnostic testing and information services in the United States. It touches over 150 million patient lives each year through comprehensive diagnostic testing services that help diagnose, monitor, predict, prevent, and treat diseases. Quest aims to be the undisputed world leader in diagnostic testing, information, and services through strategies focused on delivering superior patient experiences, leading medical innovation, leveraging its assets and capabilities, expanding diagnostic scope, and expanding its geographic reach.
Promoting Malaysia As A Trial Hub CRC As One Stop Centerleehanwei
The document summarizes Malaysia's efforts to promote clinical trials and establish itself as a regional clinical research hub. It outlines the Clinical Research Centre (CRC) as a one-stop center that can facilitate all aspects of conducting clinical trials in Malaysia, including providing investigator networks, regulatory and ethics submissions, data management, and other support services. CRC aims to make the clinical trials process efficient and help sponsors conduct trials in Malaysia. The document also highlights Malaysia's competitive advantages for clinical research such as its supportive government policies, qualified researchers, diverse patient populations, and lower costs.
When digital medicine becomes the medicine (2/2)Yoon Sup Choi
The study assessed the quality and accuracy of care provided by 8 major commercial telemedicine companies for common acute illnesses. Standardized patients presented 6 conditions and completed 599 virtual visits total. The completeness of histories and physical exams ranged from 51.7-82.4% across companies. Correct diagnoses were provided in 65.4-93.8% of visits. Adherence to clinical guidelines for management decisions was 54.3% overall but varied significantly between conditions and companies, from 34.4-66.1% across companies. Greater variation was seen for viral infections than musculoskeletal conditions. This suggests the quality of telemedicine can differ substantially between providers.
The document discusses the post-COVID-19 era and the partnership between the pharmaceutical industry and digital healthcare. It introduces Dr. Yoonsup Choi, a leading expert in digital healthcare in Korea who has published numerous papers and books on medical AI. He founded the first research institute on digital healthcare in Korea and co-founded a startup accelerator for healthcare companies. The COVID-19 pandemic has accelerated changes in healthcare and increased investment in digital health.
This document provides tips for productive FDA meetings. It advises understanding FDA's perspectives and being flexible in discussions. While FDA aims to innovate, sponsors need to show how their approaches address current needs. Agreement is not always the goal; it is better sometimes to get FDA to tolerate an approach. Meeting minutes may lack clarity, so sponsors should summarize discussion points. Experts and patients at meetings can provide value if well-prepared.
The Role of Real-World Evidence in Supporting a Product's Value StoryCovance
Randomized clinical trials (RCTs) are the gold standard for gaining regulatory approval for marketing authorization for medical products. RCTs typically measure short-term efficacy and safety of a product compared to placebo in a fairly homogeneous population and under ideal, controlled conditions. In contrast, the real world consists of a heterogeneous population in which patient care is much less controlled and thus, more complex. Treatment decisions made in this setting are predicated on a wider array of co-morbid conditions, competing medications, physician preference and risk of adverse events than those observed in RCT populations. Evidence generated from real-world settings reflects this complexity, complementing evidence derived from rigorously controlled RCTs.
1) The document discusses the history and drivers of technology adoption in healthcare settings, including improving quality, safety, efficiency and empowering patients.
2) It provides data on rates of electronic medical record utilization by practice size from 2005 and the functions of electronic health records like health information, order entry, and decision support.
3) Key stakeholders in healthcare IT certification are identified, including clinicians, vendors, payers, consumers, and government agencies.
Understand what healthcare analytics is.
Identify the 5-stage Analytics Program Lifecycle (APL).
Understand how data analytics can be used in healthcare.
Check it on Experfy: https://www.experfy.com/training/courses/introduction-to-healthcare-analytics.
18 Weeks Whole Pathways Project - National Priority Projects 07/08 Summary Document
This summary document include descriptions, supporting information and key learning from the project. Details of each project site are available in the summary document, and are linked to the priority project online resource – an interactive tool that shares the learning across all project areas (Published June 2008).
Connected Health & Me - Matic Meglic - Nov 24th 2014ipposi
This document discusses how data sharing is changing healthcare by empowering patients. It outlines a shift from a traditional care model, where patients are passive recipients of care, to one where patients are engaged and empowered through access to their own health data and contextual knowledge. Key drivers of this change include affordable technology, the quantified self-movement, big data, and empowered patients. The document discusses how patient registries and personalized medicine can utilize data to better understand treatment efficacy for similar patients and provide personalized care plans. It also notes challenges around data privacy and the need for guidelines. Overall, the document advocates for empowering patients through access to their own health data while using data and technology to coordinate and improve healthcare.
Planimeter Kft is a full service CRO specialized in translational medicine located in Budapest, Hungary. Their mission is to provide expertise in biostatistics for the pharmaceutical industry using rigorous quantitative methods. They have 16 employees and contractors who have experience in all phases of drug development. Their services include clinical trial design, data management, statistical analysis, and using new technologies like data mining and personalize medicine approaches.
1) Electronic medical records have the potential to transform medicine by serving as a platform for clinical decision support, personalized medicine, and precision medicine approaches through integration of diverse data sources.
2) Registries built from EMR data can be used to study conditions, compare treatment effectiveness, and recruit for clinical trials, with the goal of reducing the lag time between research and practice.
3) Advances in predictive modeling, diagnostic and treatment algorithms, and artificial intelligence may help optimize clinical decision making if effectively integrated into clinical workflow and EMRs.
Personalized medicine tools for clinical trials - kuchinkeWolfgang Kuchinke
Tools for personalised medicine in clinical trials. ---------
The implementation of clinical trials in personalized medicine is a different way of doing clinical research compared to the standard way of large clinical trials aiming for statistical significance. Personalized medicine uses a medical model that separates people into different groups with medical decisions, practices, drugs, interventions being tailored to the individual patient based on their predicted response. Basis for this approach is the progress of the study of the human genome and its variation over the last two decades. Especially advancement in automated DNA sequencing and PCR and the use of expressed sequence tags (ESTs), cDNAs, antisense molecules, small nterfering RNAs (siRNAs), full-length genes and their expression products and haplotypes.
But adoption of personalized medicine requires an active and flexible and highly integrated infrastructure, which allows joining of many different competences and technologies. We asked the question: can the tools developed for personalized medicine in the p-pedicine project be employed effectively in a clinical trials network to support personalised clinical trials. We conducted an analysis of tool integration and the evaluation tool usage requirements. Based on the survey results, the tendency for clinical trial network ECRIN is to use software as a service in the form as SaaS or ASP. ECRIN data centres will (probably) not install and employ p-medicine tools in one of their data centres. A robust business model for the provision of services and the implementation and employment of tools does not yet exist.
How can the personalized medicine infrastructure p-medicine and the clinical trials network ECRIN gain from each other to allow the conduct of personalized clinical trials?
We suggest a business model, in which personal medicine infrastructures and clinical trials networks exchange their services to gain jointly from each other. Therefore: an integration by reciprocal exchange of services may be the solution. Not only software as a service will be exchanged, but also knowledge, personnel and joint staff trainings.
Personalized medicine tools for clinical trials - KuchinkeWolfgang Kuchinke
Tools for personalised medicine in clinical trials.
The implementation of clinical trials in personalized medicine is a different way of doing clinical research, compared to the standard way of large clinical trials aiming for statistical significance. Personalized medicine uses a medical model that separates people into different groups with medical decisions, practices, drugs, interventions being tailored to the individual patient based on their predicted response. Basis for this approach is the progress of the study of the human genome and its variation over the last two decades. Especially advancements in automated DNA sequencing, PCR technologies and the use of expressed sequence tags (ESTs), cDNAs, antisense molecules, small interfering RNAs (siRNAs).
But the adoption of personalized medicine requires an active and flexible and highly integrated infrastructure, which must allow the joining of many different competences and technologies. We asked the question: can the tools developed for personalized medicine in the p-pedicine project be employed effectively in a clinical trials network to support personalised clinical trials? We conducted an analysis of tool integration and the evaluation of tool usage requirements. Based on the survey results, the tendency for the clinical trial network ECRIN is to use software as a service in the form of SaaS or ASP. ECRIN data centres will (probably) not install and employ p-medicine tools in one of their data centres. A robust business model for the provision of services and the implementation and employment of tools does not yet exist.
How can the personalized medicine infrastructure p-medicine and the clinical trials network ECRIN gain from each other to allow the conduct of personalized clinical trials? We suggest a business model, in which personalized medicine infrastructures and clinical trials networks exchange their services to gain jointly from each other. An integration of networks by reciprocal exchange of services may be the solution. Not only software as a service will be exchanged, but also knowledge, personnel and staff trainings.
A clinical decision support system (CDSS) is an interactive computer program that uses patient data to generate advice to help clinicians make decisions. A CDSS uses a dynamic knowledge base and rules derived from experts to make suggestions, which clinicians can then use along with their own expertise to determine diagnoses and treatments. CDSS systems are used at the point of care to assist clinicians before, during, and after making diagnoses. They work by taking in patient data, applying medical knowledge, and providing recommendations to aid clinical decision making.
IMS Health RWES: The Future of Real-World Insights in CancerIMSHealthRWES
The document discusses IMS Health's real-world evidence solutions for cancer, including their cancer data ecosystem. The ecosystem combines various real-world data sources like medical claims, EMR data, and genomic data from over 15 million anonymous cancer patients. It provides comprehensive insights through innovative analytics to help address challenges across the cancer care continuum for clinicians, payers, pharmaceutical companies, patients, and advocacy groups.
CareSolutions™ Climate–HIV is a specialized electronic patient record (EPR) system for HIV medicine that follows the clinical work streams of your HIV team to support efficient, multi-disciplinary, patient-centered care. Climate-HIV makes it easier and safer to prescribe, document patient encounters, write clinical letters and code diagnoses.
Data Science Deep Roots in Healthcare IndustryDinesh V
Data Science transforms the healthcare industry with impeccable solutions that can improve patient care through EHRs, medical imaging, drug discovery, predictive medicines and genetics and genomics.
Medical Related information reconciliation when a patient sees many providers or transfers between health facilities is challenging. Lack of updated and correct information is a key concern for patient safety during a health and illness trajectory [1]. Errors, near misses and adverse medication events are too common, particularly whne transfers between hospitals, nursing home and home are frequent, or engagement of multiple specialties is common [2]. Lack of effective informatics support can be harmful to a person’s health, leading to suffering, increased use of health care resources and increased costs.
As a case for interactive discussion, we have chosen information exchanges related to medication, prescription-based as well as over the counter drugs. This challenging chain of activities includes: (a) prescribing on paper or electronically by several medical specialists, (b) transcribing by sending and interpreting prescriptions in the pharmacy, (c) dispensing medication by brand name or generic substitution, (d) acquiring over the counter medication, (e) administering medication as a user, and (f) observing effects and side-effects. The risk of missing information leading to mistakes in the chain of activities in medication management is likely to increase as complex medication regimes become common due to demographic developments, co-morbidities or more personalized treatment. Potentials in patient activation and relevant informatics tools for medication reconciliation need further exploration.
Anne MOEN Institute for Health and Society, Faculty of Medicine, University of Oslo, NORWAY
Catherine CHRONAKI HL7 Foundation, Brussels, BELGIUM
Christian NØHR, Aalborg University, DENMARK
Line Helen LINSTAD Norwegian Center for eHealth Research, Tromsø, NORWAY
Petter HURLEN Akershus University Hospital, NORWAY
This document discusses patient generated data (PGD) and how mobile health (mHealth) technologies can be used to capture it. PGD includes data recorded by patients about their health symptoms, medication adherence, biometric data from wearables, and patient reported outcomes. The document outlines how PGD can help with clinical trials and care by providing more comprehensive real-world data. Challenges with PGD like data quality, privacy and regulatory issues are discussed. The document provides examples of how the Aparito platform captures different types of PGD through mobile apps and connected devices to improve disease understanding and drug development.
Quest Diagnostics is the leader in diagnostic testing and information services in the United States. It touches over 150 million patient lives each year through comprehensive diagnostic testing services that help diagnose, monitor, predict, prevent, and treat diseases. Quest aims to be the undisputed world leader in diagnostic testing, information, and services through strategies focused on delivering superior patient experiences, leading medical innovation, leveraging assets and capabilities, expanding diagnostic scope and geographic reach, and reducing costs.
This document describes a health and hospital management system that provides electronic medical records, hospital information systems, and health information systems. It allows doctors to store patients' clinical histories, prescriptions, lab results, and more. Hospitals can use it to manage resources, employees, billing, and inventory. It also provides functionalities for laboratory tests, patient registration and appointments, genetics, gynecology, billing, and tracking patients' lifestyles and socioeconomic data. The system offers flexibility, integration, security, and scalability at no licensing cost to users.
The document discusses the post-COVID-19 era and the partnership between the pharmaceutical industry and digital healthcare. It introduces Dr. Yoonsup Choi, a leading expert in digital healthcare in Korea who has published numerous papers and books on medical AI. He founded the first research institute on digital healthcare in Korea and co-founded a startup accelerator for healthcare companies. The COVID-19 pandemic has accelerated changes in healthcare and increased investment in digital health.
This document provides tips for productive FDA meetings. It advises understanding FDA's perspectives and being flexible in discussions. While FDA aims to innovate, sponsors need to show how their approaches address current needs. Agreement is not always the goal; it is better sometimes to get FDA to tolerate an approach. Meeting minutes may lack clarity, so sponsors should summarize discussion points. Experts and patients at meetings can provide value if well-prepared.
The Role of Real-World Evidence in Supporting a Product's Value StoryCovance
Randomized clinical trials (RCTs) are the gold standard for gaining regulatory approval for marketing authorization for medical products. RCTs typically measure short-term efficacy and safety of a product compared to placebo in a fairly homogeneous population and under ideal, controlled conditions. In contrast, the real world consists of a heterogeneous population in which patient care is much less controlled and thus, more complex. Treatment decisions made in this setting are predicated on a wider array of co-morbid conditions, competing medications, physician preference and risk of adverse events than those observed in RCT populations. Evidence generated from real-world settings reflects this complexity, complementing evidence derived from rigorously controlled RCTs.
1) The document discusses the history and drivers of technology adoption in healthcare settings, including improving quality, safety, efficiency and empowering patients.
2) It provides data on rates of electronic medical record utilization by practice size from 2005 and the functions of electronic health records like health information, order entry, and decision support.
3) Key stakeholders in healthcare IT certification are identified, including clinicians, vendors, payers, consumers, and government agencies.
Understand what healthcare analytics is.
Identify the 5-stage Analytics Program Lifecycle (APL).
Understand how data analytics can be used in healthcare.
Check it on Experfy: https://www.experfy.com/training/courses/introduction-to-healthcare-analytics.
18 Weeks Whole Pathways Project - National Priority Projects 07/08 Summary Document
This summary document include descriptions, supporting information and key learning from the project. Details of each project site are available in the summary document, and are linked to the priority project online resource – an interactive tool that shares the learning across all project areas (Published June 2008).
Connected Health & Me - Matic Meglic - Nov 24th 2014ipposi
This document discusses how data sharing is changing healthcare by empowering patients. It outlines a shift from a traditional care model, where patients are passive recipients of care, to one where patients are engaged and empowered through access to their own health data and contextual knowledge. Key drivers of this change include affordable technology, the quantified self-movement, big data, and empowered patients. The document discusses how patient registries and personalized medicine can utilize data to better understand treatment efficacy for similar patients and provide personalized care plans. It also notes challenges around data privacy and the need for guidelines. Overall, the document advocates for empowering patients through access to their own health data while using data and technology to coordinate and improve healthcare.
Planimeter Kft is a full service CRO specialized in translational medicine located in Budapest, Hungary. Their mission is to provide expertise in biostatistics for the pharmaceutical industry using rigorous quantitative methods. They have 16 employees and contractors who have experience in all phases of drug development. Their services include clinical trial design, data management, statistical analysis, and using new technologies like data mining and personalize medicine approaches.
1) Electronic medical records have the potential to transform medicine by serving as a platform for clinical decision support, personalized medicine, and precision medicine approaches through integration of diverse data sources.
2) Registries built from EMR data can be used to study conditions, compare treatment effectiveness, and recruit for clinical trials, with the goal of reducing the lag time between research and practice.
3) Advances in predictive modeling, diagnostic and treatment algorithms, and artificial intelligence may help optimize clinical decision making if effectively integrated into clinical workflow and EMRs.
Personalized medicine tools for clinical trials - kuchinkeWolfgang Kuchinke
Tools for personalised medicine in clinical trials. ---------
The implementation of clinical trials in personalized medicine is a different way of doing clinical research compared to the standard way of large clinical trials aiming for statistical significance. Personalized medicine uses a medical model that separates people into different groups with medical decisions, practices, drugs, interventions being tailored to the individual patient based on their predicted response. Basis for this approach is the progress of the study of the human genome and its variation over the last two decades. Especially advancement in automated DNA sequencing and PCR and the use of expressed sequence tags (ESTs), cDNAs, antisense molecules, small nterfering RNAs (siRNAs), full-length genes and their expression products and haplotypes.
But adoption of personalized medicine requires an active and flexible and highly integrated infrastructure, which allows joining of many different competences and technologies. We asked the question: can the tools developed for personalized medicine in the p-pedicine project be employed effectively in a clinical trials network to support personalised clinical trials. We conducted an analysis of tool integration and the evaluation tool usage requirements. Based on the survey results, the tendency for clinical trial network ECRIN is to use software as a service in the form as SaaS or ASP. ECRIN data centres will (probably) not install and employ p-medicine tools in one of their data centres. A robust business model for the provision of services and the implementation and employment of tools does not yet exist.
How can the personalized medicine infrastructure p-medicine and the clinical trials network ECRIN gain from each other to allow the conduct of personalized clinical trials?
We suggest a business model, in which personal medicine infrastructures and clinical trials networks exchange their services to gain jointly from each other. Therefore: an integration by reciprocal exchange of services may be the solution. Not only software as a service will be exchanged, but also knowledge, personnel and joint staff trainings.
Personalized medicine tools for clinical trials - KuchinkeWolfgang Kuchinke
Tools for personalised medicine in clinical trials.
The implementation of clinical trials in personalized medicine is a different way of doing clinical research, compared to the standard way of large clinical trials aiming for statistical significance. Personalized medicine uses a medical model that separates people into different groups with medical decisions, practices, drugs, interventions being tailored to the individual patient based on their predicted response. Basis for this approach is the progress of the study of the human genome and its variation over the last two decades. Especially advancements in automated DNA sequencing, PCR technologies and the use of expressed sequence tags (ESTs), cDNAs, antisense molecules, small interfering RNAs (siRNAs).
But the adoption of personalized medicine requires an active and flexible and highly integrated infrastructure, which must allow the joining of many different competences and technologies. We asked the question: can the tools developed for personalized medicine in the p-pedicine project be employed effectively in a clinical trials network to support personalised clinical trials? We conducted an analysis of tool integration and the evaluation of tool usage requirements. Based on the survey results, the tendency for the clinical trial network ECRIN is to use software as a service in the form of SaaS or ASP. ECRIN data centres will (probably) not install and employ p-medicine tools in one of their data centres. A robust business model for the provision of services and the implementation and employment of tools does not yet exist.
How can the personalized medicine infrastructure p-medicine and the clinical trials network ECRIN gain from each other to allow the conduct of personalized clinical trials? We suggest a business model, in which personalized medicine infrastructures and clinical trials networks exchange their services to gain jointly from each other. An integration of networks by reciprocal exchange of services may be the solution. Not only software as a service will be exchanged, but also knowledge, personnel and staff trainings.
A clinical decision support system (CDSS) is an interactive computer program that uses patient data to generate advice to help clinicians make decisions. A CDSS uses a dynamic knowledge base and rules derived from experts to make suggestions, which clinicians can then use along with their own expertise to determine diagnoses and treatments. CDSS systems are used at the point of care to assist clinicians before, during, and after making diagnoses. They work by taking in patient data, applying medical knowledge, and providing recommendations to aid clinical decision making.
IMS Health RWES: The Future of Real-World Insights in CancerIMSHealthRWES
The document discusses IMS Health's real-world evidence solutions for cancer, including their cancer data ecosystem. The ecosystem combines various real-world data sources like medical claims, EMR data, and genomic data from over 15 million anonymous cancer patients. It provides comprehensive insights through innovative analytics to help address challenges across the cancer care continuum for clinicians, payers, pharmaceutical companies, patients, and advocacy groups.
CareSolutions™ Climate–HIV is a specialized electronic patient record (EPR) system for HIV medicine that follows the clinical work streams of your HIV team to support efficient, multi-disciplinary, patient-centered care. Climate-HIV makes it easier and safer to prescribe, document patient encounters, write clinical letters and code diagnoses.
Data Science Deep Roots in Healthcare IndustryDinesh V
Data Science transforms the healthcare industry with impeccable solutions that can improve patient care through EHRs, medical imaging, drug discovery, predictive medicines and genetics and genomics.
Medical Related information reconciliation when a patient sees many providers or transfers between health facilities is challenging. Lack of updated and correct information is a key concern for patient safety during a health and illness trajectory [1]. Errors, near misses and adverse medication events are too common, particularly whne transfers between hospitals, nursing home and home are frequent, or engagement of multiple specialties is common [2]. Lack of effective informatics support can be harmful to a person’s health, leading to suffering, increased use of health care resources and increased costs.
As a case for interactive discussion, we have chosen information exchanges related to medication, prescription-based as well as over the counter drugs. This challenging chain of activities includes: (a) prescribing on paper or electronically by several medical specialists, (b) transcribing by sending and interpreting prescriptions in the pharmacy, (c) dispensing medication by brand name or generic substitution, (d) acquiring over the counter medication, (e) administering medication as a user, and (f) observing effects and side-effects. The risk of missing information leading to mistakes in the chain of activities in medication management is likely to increase as complex medication regimes become common due to demographic developments, co-morbidities or more personalized treatment. Potentials in patient activation and relevant informatics tools for medication reconciliation need further exploration.
Anne MOEN Institute for Health and Society, Faculty of Medicine, University of Oslo, NORWAY
Catherine CHRONAKI HL7 Foundation, Brussels, BELGIUM
Christian NØHR, Aalborg University, DENMARK
Line Helen LINSTAD Norwegian Center for eHealth Research, Tromsø, NORWAY
Petter HURLEN Akershus University Hospital, NORWAY
This document discusses patient generated data (PGD) and how mobile health (mHealth) technologies can be used to capture it. PGD includes data recorded by patients about their health symptoms, medication adherence, biometric data from wearables, and patient reported outcomes. The document outlines how PGD can help with clinical trials and care by providing more comprehensive real-world data. Challenges with PGD like data quality, privacy and regulatory issues are discussed. The document provides examples of how the Aparito platform captures different types of PGD through mobile apps and connected devices to improve disease understanding and drug development.
Quest Diagnostics is the leader in diagnostic testing and information services in the United States. It touches over 150 million patient lives each year through comprehensive diagnostic testing services that help diagnose, monitor, predict, prevent, and treat diseases. Quest aims to be the undisputed world leader in diagnostic testing, information, and services through strategies focused on delivering superior patient experiences, leading medical innovation, leveraging assets and capabilities, expanding diagnostic scope and geographic reach, and reducing costs.
This document describes a health and hospital management system that provides electronic medical records, hospital information systems, and health information systems. It allows doctors to store patients' clinical histories, prescriptions, lab results, and more. Hospitals can use it to manage resources, employees, billing, and inventory. It also provides functionalities for laboratory tests, patient registration and appointments, genetics, gynecology, billing, and tracking patients' lifestyles and socioeconomic data. The system offers flexibility, integration, security, and scalability at no licensing cost to users.
Big data, RWE and AI in Clinical Trials made simpleHadas Jacoby
Technology is slowly but surely penetrating the healthcare industry in general and the clinical trials sector in particular. New and advanced solutions offer a variety of possibilities aimed to both improving existing processes and creating new and more efficient ones. And on top of all stands the desire to make clinical trials more patient centric.
In all of this, even though some of the technologies have yet to mature enough to meet the high quality standards necessary, it is important to know them and begin imagining the promise they hold for clinical trials.
What are today's challenges of big medical data and how can we use the immense data to turn it into potentials, e.g. for precision medicine. Get insights in application examples, where big medical data are incorporated and how in-memory database technology can enable it instantaneous analysis.
To learn more visit:
https://insidescientific.com/webinar/cutting-edge-conversations-fighting-neurodegenerative-diseases/
Evelyn Pyper, MPH discusses how a patient-centered approach to real-world data collection and evidence generation can transform research in neurodegeneration. Neurodegenerative diseases often affect both motor and cognitive function, produce emotional and social changes, and require significant caregiver support, all while stretching across a fragmented healthcare ecosystem. Participatory research that directly obtains patient consent, empowers patients, and simplifies the task of linking multiple data sources, can lead to a more comprehensive capture of medical histories. This presentation briefly explores ways in which patient-centered research can improve understanding of disease diagnoses, symptomatology, and progression.
IMS Health Enriched Real-World Data StudyIMSHealthRWES
1) Researchers developed the DIAREG registry in Germany using a mixed methods approach to overcome limitations of electronic medical record databases which often lack critical variables.
2) The registry links retrospective data from electronic medical records with prospective clinical data collected through electronic case report forms and patient-reported outcomes to create a rich data resource.
3) As of September 2014, the DIAREG registry contained data on 1,071 diabetes patients in Germany, enabling granular observational research on relationships and outcomes that were previously difficult to study.
Digital therapeutics (DTx) are software-based interventions used to treat, manage, or prevent disease. They are clinically evaluated and evidence-based. DTx are regulated as software as a medical device (SaMD) and follow a similar regulatory pathway to medical devices, though a formal SaMD pathway is still under development. DTx development involves proof of concept studies, pilot studies, and pivotal randomized controlled trials to demonstrate safety, efficacy, and usability. Post-market, real world performance and user experience data are collected to monitor continued effectiveness and safety. Commercialization involves educating providers and payers while pathways to scale remain uncertain in this emerging market.
Similar to DESTINY – An Innovative Platform for Personalized Medicine from Doctors for Doctors & Patients (20)
Keerthivasan Kunchithapatham Pillai, Co-Founder of Linux Laboratories on the topic of 'M Health – A Revolution' at IFAH held at Le Meridien, Dubai on 16th - 18th December, 2019.
Meaningful Access To Healthcare - The Good, The Bad - The Future of Healthcar...IFAH
Manish Chabbra, Founder & CEO, Shifa International FZ- LLC on the topic of 'Meaningful Access To Healthcare - The Good, The Bad - The Future of Healthcare With Technology' at IFAH held at Le Meridien, Dubai on 16th - 18th December, 2019.
Blockchain Technology In Healthcare As A Trustworthy Solution For IoTIFAH
Pravash Dey, Disruptor-In-Chief, US India Blockchain Council on the topic of 'Blockchain Technology In Healthcare As A Trustworthy Solution For IoT' at IFAH held at Le Meridien, Dubai on 16th - 18th December, 2019.
This document discusses emerging trends in healthcare and wellness, including the rise of integrated medical wellness centers and resorts. It notes the growing demand for preventative and functional healthcare options as populations age and adopt healthier lifestyles. Examples of potential integrated medical wellness developments across Southeast Asia are provided, combining elements of medicine, wellness, hospitality and active living communities. Key opportunities exist in developing more of these types of mixed-use centers that incorporate both medical and wellness programs.
Dr. Ruchi Dana, President & COO, Duluth Medical Technologies Inc. on the topic of 'Work & Life In The Age Of AI & Robots' at IFAH held at Le Meridien, Dubai on 16th - 18th December, 2019.
The Role Of Data and Emergent Technologies In Managing Health IFAH
This document discusses 5 trends in the healthcare industry driven by increased data availability and data-sharing: 1) Increased sharing of data across the healthcare ecosystem, 2) Nanomedicine, sensors, and AI driving innovation through increased data capture, 3) Emergence of a "digital backbone" across the industry but uncertainty around who will own it, 4) Growing empowerment and influence of patients over other stakeholders, 5) Specialized business models positioning companies to outperform through focus on data capabilities aligned to business models.
Raj Bhogal, Head of Regulatory Inspections, R&D Quality Takeda on the topic of 'Pharmacovigilance Inspections' at IFAH held at Le Meridien, Dubai on 16th - 18th December, 2019.
Sir Ganga Ram Hospital Model: A Different Model for Healthcare DeliveryIFAH
Dr. Ajay Swaroop, Honorary Secretary cum Treasurer - Board of Management at Sir Ganga Ram Hospital on the topic of 'Sir Ganga Ram Hospital Model: A Different Model for Healthcare Delivery' at IFAH held at Le Meridien, Dubai on 16th - 18th December, 2019.
Dr. Pramod Tripathi, Founder, Freedom From Diabetes Pvt Ltd on the topic of 'Reversing Diabetes and Lifestyle Disorders' at IFAH held at Le Meridien, Dubai on 16th - 18th December, 2019.
Innovative Approaches To Service For Patients In Pharma SectorIFAH
Takeda is a global values-based biopharmaceutical company committed to developing innovative treatments to improve patient health. The presentation discusses Takeda's acquisition of Shire which expanded its therapeutic areas and pipeline. It also outlines Takeda's R&D strategy which focuses on developing new treatments in oncology, gastroenterology, neuroscience, and rare diseases. Additionally, the presentation notes Takeda is exploring innovative approaches beyond traditional medicines, such as cell, gene, and RNA therapies, to serve more patients.
Michael Phillips Moskowitz, Founder/CEO of AeBeZe Labs and Moodrise, on the topic of 'Digital Nutrition' at IFAH held at Le Meridien, Dubai on 16th - 18th December, 2019.
Evolution Of Traditional Medical Devices IndustryIFAH
A session by Bruce Huici, Founder & CEO, Hallstat on the topic of 'Evolution Of Traditional Medical Devices Industry' at IFAH USA 2019 held at Caesars Palace, 18-20 June, 2019.
A session by Susan P. Gibson, President & Founder, Vivolor Therapeutics, Inc. on the topic of 'Is Pharma Drug Pricing Being Disrupted?' at IFAH USA 2019 held at Caesars Palace, 18-20 June, 2019.
1) The document discusses a study utilizing a proprietary cardiovascular management system and remote heart management system to provide computer assisted medication management and precision medicine modeling for 394 outpatients with chronic cardiovascular disease.
2) The remote heart management system utilized machine learning techniques like supervised and unsupervised learning to provide predictive diagnostics and a precision medicine model.
3) Results found lower 30-day readmission rates and 1-year hospitalization rates compared to controls, demonstrating the potential of machine learning and remote monitoring to improve outcomes for heart failure patients.
Invisible But Indispensable: Caregivers In An Aging WorldIFAH
A session by Dr. Aaron Blight, Founder, Caregiving Kinetics on the topic of 'Invisible But Indispensable: Caregivers In An Aging World' at IFAH USA 2019 held at Caesars Palace, 18-20 June, 2019.
Population Health Management & Volume To Value Based CareIFAH
A session by Amish Purohit, CEO and CMO, US Health Systems on the topic of 'Population Health Management & Volume To Value Based Care' at IFAH USA 2019 held at Caesars Palace, 18-20 June, 2019.
Photobiomodulation, Biophysics and Energy Medicine Technology: The Science an...IFAH
A session by Leanne Venier, CEO, Leanne Venier International on the topic of 'Photobiomodulation, Biophysics and Energy Medicine Technology: The Science and Practical Applications of Treating at the Root of Illness and Disease' at IFAH USA 2019 held at Caesars Palace, 18-20 June, 2019.
Accounting & Financial Reporting In Healthcare InstitutionsIFAH
A session by Will Schmidt, CEO & Founder, RxSuccess Consulting on the topic of 'Accounting & Financial Reporting In Healthcare Institutions' at IFAH USA 2019 held at Caesars Palace, 18-20 June, 2019.
Blockchain Innovation In Healthcare & Life SciencesIFAH
A session by Michael Irish, CEO, Vivacitas Healthcare on the topic of 'Blockchain Innovation In Healthcare & Life Sciences' at IFAH USA 2019 held at Caesars Palace, 18-20 June, 2019.
End-tidal carbon dioxide (ETCO2) is the level of carbon dioxide that is released at the end of an exhaled breath. ETCO2 levels reflect the adequacy with which carbon dioxide (CO2) is carried in the blood back to the lungs and exhaled.
Non-invasive methods for ETCO2 measurement include capnometry and capnography. Capnometry provides a numerical value for ETCO2. In contrast, capnography delivers a more comprehensive measurement that is displayed in both graphical (waveform) and numerical form.
Sidestream devices can monitor both intubated and non-intubated patients, while mainstream devices are most often limited to intubated patients.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...rightmanforbloodline
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
Joker Wigs has been a one-stop-shop for hair products for over 26 years. We provide high-quality hair wigs, hair extensions, hair toppers, hair patch, and more for both men and women.
R3 Stem Cell Therapy: A New Hope for Women with Ovarian FailureR3 Stem Cell
Discover the groundbreaking advancements in stem cell therapy by R3 Stem Cell, offering new hope for women with ovarian failure. This innovative treatment aims to restore ovarian function, improve fertility, and enhance overall well-being, revolutionizing reproductive health for women worldwide.
The Importance of Black Women Understanding the Chemicals in Their Personal C...bkling
Certain chemicals, such as phthalates and parabens, can disrupt the body's hormones and have significant effects on health. According to data, hormone-related health issues such as uterine fibroids, infertility, early puberty and more aggressive forms of breast and endometrial cancers disproportionately affect Black women. Our guest speaker, Jasmine A. McDonald, PhD, an Assistant Professor in the Department of Epidemiology at Columbia University in New York City, discusses the scientific reasons why Black women should pay attention to specific chemicals in their personal care products, like hair care, and ways to minimize their exposure.
As Mumbai's premier kidney transplant and donation center, L H Hiranandani Hospital Powai is not just a medical facility; it's a beacon of hope where cutting-edge science meets compassionate care, transforming lives and redefining the standards of kidney health in India.
At Malayali Kerala Spa Ajman, Full Service includes individualized care for every client. We specifically design each massage session for the individual needs of the client. Our therapists are always willing to adjust the treatments based on the client's instruction and feedback. This guarantees that every client receives the treatment they expect.
By offering a variety of massage services, our Ajman Spa Massage Center can tackle physical, mental, and emotional illnesses. In addition, efficient identification of specific health conditions and designing treatment plans accordingly can significantly enhance the quality of massaging.
At Malayali Kerala Spa Ajman, we firmly believe that everyone should have the option to experience top-quality massage services regularly. To achieve that goal we offer cheap massage services in Ajman.
If you are interested in experiencing transformative massage treatment at Malayali Kerala Spa Ajman, you can use our Ajman Massage Center WhatsApp Number to schedule your next massage session.
Contact @ +971 529818279
Visit @ https://malayalikeralaspaajman.com/
This particular slides consist of- what is Pneumothorax,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is a summary of Pneumothorax:
Pneumothorax, also known as a collapsed lung, is a condition that occurs when air leaks into the space between the lung and chest wall. This air buildup puts pressure on the lung, preventing it from expanding fully when you breathe. A pneumothorax can cause a complete or partial collapse of the lung.
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
DESTINY – An Innovative Platform for Personalized Medicine from Doctors for Doctors & Patients
1. DESTINY – an innovative platform for personalized
medicine from doctors for doctors & patients
Dubai, 16.12.2019
2. • Foundedin2008
• Network of 136 Neurologists/ Psychiatrists specialistsacross72
practices
• Distributed acrossGermany in 4 districts (North-East,North-West,
South-East, South-West)
• Standardised, fully digital, and ISO-certified office-based EMR
systemwith centralised cloud-based database - updated daily
• ~600,000 patients with neurological or psychiatric diseases**;
~25,000 MSpatients acrossdiseasesubtypes with back-data to
2008
• Cooperation with several universitiesin Germany and abroad
(Munich,Essen,Nuremberg, Basel,Zurich, Stanford)
• Approval by EthicsCommitteeof the Bavarian Medical Board as
well asEthicsCommitteeof the Medical BoardNorth-Rhine
NeuroTransData
Physiciannetworkneurology/psychiatry
2 NeuroTransData GmbH / NeuroTransConcept GmbH
5. Hard criteria (must-have)
5 NeuroTransData GmbH / NeuroTransConcept GmbH
• Certified according to ISO-Standard
• Authorization for post-graduate medical education in subject area
• Integrated standardised continuoustraining (e.g. via Virtual Classrooms)
for physicians and assistants(e.g. GCP,E-Diagnostics,Coaching)
• Utilisation of the NTD-Database
• Complete modern equipment, at least consistingof EEG,EMG/NCS,
CCDS(extracranial and evoked potentials)
6. Hard criteria (must-have)
6 NeuroTransData GmbH / NeuroTransConcept GmbH
• Fully digitalised practice with modern meansof communication(at least
T-DSLor the like)
• Consistentutilisation of theinternet
• Sufficient numberof physicians and medical personnel / healthcare
professionals
• Handicapped-suited accessand facilities
7. Furthercriteria (should-have)
7 NeuroTransData GmbH / NeuroTransConcept GmbH
• Neurologists at least
Nervenärzte at least
Psychiatristsatleast
900 panel patients/quarter/panel doctor
750 panel patients/quarter/panel doctor
450 panel patients/quarter/panel doctor
• Utilisation of a „positive list“ (medications)aswell asdiagnostics and therapy
conceptsin pre-defined indications
• Mustbe able to perform
• Lumbar puncture
• Infusion
• Observation room
• Conduct of clinical trials
8. Furthercriteria (should-have)
8 NeuroTransData GmbH / NeuroTransConcept GmbH
• Possibility to perform an MRTwithin 1-2 days (cooperation with a
radiologist or hospital), aswell asan on-site laboratory to assess
relevant parameters (e.g. CSF)or cooperation with a laboratory /
hospital
• Location, public transport, parking
• Publicrelations and development of a „Corporate Identity“ (outward
and inward)
11. DESTINY®– the patient-centered benefit model
DatabasE-assiSted Therapy decIsioN support sYstem
NTD Registry Database
External Registries/
Databases
Doctor Nurse
Patient Patient and doctor portal
My NTC Health Guide
PCTablet
Wearable App
External clinics, doctors
and healthcareproviders
Bidirectional
data transfer
Data entry & upload
Visualization and
eHealth application
Automatic MRI
evaluation & report
(via service provider)
Medication chart
Allergies and
intolerances
Findings and lab values
Vaccination and
vaccination plan
MRI images
Diagnosis and
clinical documentation
Treatment information
and implants
Medical reports
Modules for
therapy decisionsupport
PHREND
Therapy
optimization
Safety-Management
Tool
Biomarker
ELISPOT-test
Automated
Cognitive Platform
Drug Interactions
PGXperts
External systems
e.g.
powered by
“Fromdoctorsfor doctors& patients”
Upload
12. Module PHREND®
Predictive Healthcare with RealWorld Evidencefor Neurological Disorders
App providing personalized
comparisonsof treatment
effectiveness usingreal world
evidencedata (RWE)
Rollout to German doctor’s
offices starting early 2018
Pilot in NTDoffices launched
August 2017
Machinelearning and
statistical modelapplied for
clinical outcomes
Web-based tool providing
personalized comparisonsof
treatmenteffectivenessusingreal
world evidence (RWE)
Machinelearning / statistical
model used
RWEprovided by NTDcovering
20% of GermanMS patients
Currently 12 easy-to-enter input
variables for the doctor
Publishedinacademicliterature
(BMCMedical Research
Methodology)
CEcertified asmedical device
(classIapproved, classIIa in
progress)
12
22. Propensity Score Matching (PSM) schafft vergleichbare
Patientenpopulationen (Reduktion des “Indication Bias”)
0.39398
0.82922 0.15441
0.79748
0.39758
0.79743
0.67654
0.75222 0.98011
0.91542
0.24591
0.33322
0.81951
0.48123
0.35998
0.22123
0.76720
0.39221
0.07739
0.00233
0.91924
0.28007
0.69792
0.74700
0.33386
0.42549
Patienten Therapie A Patienten Therapie B
Matching
nach
PSM score
10 0.5
▸Der Propensity Score (PS) gibt die Wahrscheinlichkeit an, mit der ein Patient die Therapie A erhält.
Er wird aus einem Set an Baseline-Charakteristiken berechnet.
VOR MATCHING NACH MATCHING
Extrahierte Paare
nach dem Matching
0.69792 0.67654 0.33386 0.33322
0.91542 0.91924 0.7607.75222
20
0.81951 0.82922 0.39758 0.39398
0.35998 0.22123 0.48123
0.28007 0.39221 0.79748
0.00233 0.07739 0.15441
Patienten
ohne Match
Patienten
ohne Match
Patienten Therapie A
Patienten Therapie B
10 0.5
0.98011
0.7974
3
0.74591
23. DMF,delayed-release dimethyl fumarate; NTD,NeuroTransData.
Matching NTD populations: DMF vs fingolimod
0.0
0.5
1.5
2.0
Density 1.0
0.00 0.25 0.75 1.000.50
Propensityscore
BEFORE 1:1 MATCHING
0.0
0.5
1.0
1.5
2.0
Density
0.00 0.25 0.75 1.000.50
Propensityscore
AFTER 1:1 MATCHING
Fingolimod
DMF
26. Therapieplan.Plus
With individualized information, instructionsand medication schedulefor patients
Therapy plan Individual information Patient diary Medication schedule
26 NeuroTransData GmbH / NeuroTransConcept GmbH
27. Individualized information channelfor patients
Theright information for the
right patient at the right time.
27
• General information about disease&
treatmentoptions
• Information about therapy support
programs and services
• Product-specificinformation
• Special instructionsfor medication intake
28. Connectingall actors in the healthcare system
28 NeuroTransData GmbH / NeuroTransConcept GmbH
30. sConceptGmbH
Benefits for patients & doctors
Advantages for patients
• Platform tailored to individualpatient
characteristics
• Interaction with treating physician outside
of office hours, enhancement of
communication between doctor and
patient
• Bidirectional data exchange patient/doctor
• Visualization of clinical data, active
involvement of patients in treatment
process
• Improved control and coping with disease,
higher treatment success
• Information about new developments,
supportive measurements and services
Advantages for doctors
• Optimization of interaction between
doctor and patient
• Enhancement of patients‘ loyalty
• Improved therapy control
• Higher adherence, compliance and
treatment success
• Reputation as modern, state-of-the-art
practice
• Support of doctor and medical personnel
in daily practice
“New waysto improveyour health.”
30 NeuroTransData GmbH / NeuroTran
31. Futuremodel – value-based payment for healthcare systems
31 NeuroTransData GmbH / NeuroTransConcept GmbH
32. Leverage PwCand NTDexpertise to scaleDESTINYto other disease areas
Destiny
Other Disease Areas
32 NeuroTransData GmbH / NeuroTransConcept GmbH
33. DESTINY®– the patient-centered benefit model
DatabasE-assiSted Therapy decIsioN support sYstem
NTD Registry Database
External Registries/
Databases
Doctor Nurse
Patient Patient and doctor portal
My NTC Health Guide
PCTablet
External clinics, doctors
and healthcareproviders
Bidirectional
data transfer
Data entry & upload
Visualization and
eHealth application
Automatic MRI
evaluation & report
(via service provider)
Medication chart
Allergies and
intolerances
Findings and lab values
Vaccination and
vaccination plan
MRI images
Diagnosis and
clinical documentation
Treatment information
and implants
Medical reportsTherapy
optimization
Biomarker
ELISPOT-test
Drug Interactions
PGXperts
Modules for
therapy decisionsupport
PHREND
Automated
Cognitive Platform
Safety-
Management Tool
External systems
e.g.
powered by
Upload Wearable App
NeuroTransData GmbH / NeuroTransConcept GmbH